Anlotinib Plus Sintilimab as First-line Treatment for Advanced Non Clear Cell Renal Cell Carcinoma

NCT05220267 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Non Clear Cell Renal Carcinoma

Interventions

DRUG: Anlotinib plus Sintilimab

Sponsor

Sun Yat-sen University